Spots Global Cancer Trial Database for Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy
Official Title: Non-interventional, Prospective Study of Safety and Efficiency of the Drug Remaxol® (NTFF POLYSAN Ltd., Russia) in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy.
Study ID: NCT05789797
Interventions
Study Description
Brief Summary: Cancer has moved from the tenth place to the second one over the last 100 years, being inferior to only cardiovascular diseases in morbidity and mortality. 40 % of hepatitis cases in patients older than 40 years and 25 % of cases of fulminant hepatic failure (FHF) are caused by drug hepatic toxicity. Cases of acute drug-induced hepatitis (ADIH) make 15-20 % of patients with fulminant hepatitis in Western Europe.
Detailed Description:
Eligibility
Minimum Age: 40 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
State Budget-Funded Health Institution Kryzhanovsky Krasnoyarsk Krai Clinical Cancer Centre, Krasnoyarsk, , Russian Federation
North-West Center of Evidence-Based Medicine, Saint Petersburg, , Russian Federation
Pirogov Clinic of High Medical Technologies, St. Petersburg State University, Saint Petersburg, , Russian Federation
St. Petersburg State Budget-Funded Health Institution City Clinical Cancer Centre, St. Petersburg, , Russian Federation
Republican Clinical Cancer Centre, Ufa, , Russian Federation
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
